NCBiotech News

Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.

Durham’s BioCryst Pharmaceuticals has landed a new federal contract totaling $44 million and added some $3 million to an existing contract to support the development of galidesivir as a possible COVID-19 treatment.

bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.

News of the first U.S. coronavirus case hit the American public on Tuesday, Jan. 21. For Jessilyn Dunn, PhD, assistant professor in the Departments of Biomedical Engineering and Biostatistics and Bioinformatics at Duke University and director of the Duke BIG IDEAs Lab, the infection in Washington State was a cue to launch a new study⁠—CovIdentify.

RTP's APIE Therapeutics has signed a licensing agreement with RTI International to develop a class of RTI-developed compounds targeting heart failure and lung disease.

A research program developed by the North Carolina Biotechnology Center is exploring the potential for purple carrots to become the state's next signature cash crop.

Durham based BioAgilytix Labs has partnered with Boston’s Brio Systems to launch a platform to provide U.S. employers comprehensive COVID-19 testing programs.

Durham's Pairwise uses its gene editing technology to harness nutrient-rich, pest-resistant qualities of the leafy green Brassica juncea while diminishing pungent flavor.

Merz Therapeutics, with North American headquarters in Raleigh, has gained a new use for Xeomin, its botulinum toxin therapy.

Durham's IMMvention Therapeutix, which discovers and develops therapies that inhibit inflammation, was one of three finalists in LaunchBio’s Big Pitch competition for the most promising life science or biotech startup in the United States.

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Leading life sciences magazine PharmaVoice has named three North Carolina executives to its list of the 100 most inspiring leaders in the pharmaceutical industry.

G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, has reached an important regulatory milestone for its potential therapy for small cell lung cancer.

Durham food tech startup Pairwise enters agreement with California's Plant Sciences, Inc. to blend CRISPR gene-editing technology with germplasm of existing berries to create new varieties.